Ocular Therapeutix (OCUL) Accumulated Expenses (2013 - 2026)

Ocular Therapeutix's Accumulated Expenses history runs 14 years deep, the most recent figure standing at $36.5 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 335.25% year-over-year to $36.5 million in Q1 2026; TTM through Mar 2026 was $36.5 million, a 335.25% increase from a year earlier, with the FY2025 full-year figure at $43.8 million, up 24.83% from the prior year.
• Accumulated Expenses fell to $36.5 million in Q1 2026 per OCUL's latest filing, from $43.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $43.8 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $22.0 million (2023), against an average of $21.3 million.
• Across the five-year window, Accumulated Expenses jumped 524.8% in 2023 and plunged 75.6% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $24.1 million in 2022, then tumbled by 66.15% to $8.2 million in 2023, then surged by 330.57% to $35.1 million in 2024, then gained by 24.83% to $43.8 million in 2025, then fell by 16.76% to $36.5 million in 2026.
• Per Business Quant, the three latest OCUL Accumulated Expenses figures stand at $36.5 million (Q1 2026), $43.8 million (Q4 2025), and $40.3 million (Q3 2025).